No Data
Meihao Medical (301363.SZ) has repurchased a cumulative total of 1.9689 million shares, with a total cost of 50.0937 million yuan.
Mei Hao Medical (301363.SZ) announced that as of July 31, 2024, the company will trade through centralized competitive bidding...
The Returns On Capital At MeHow Innovative (SZSE:301363) Don't Inspire Confidence
As of July 19, 2024, the total number of shareholders of Meihao Medical (301363.SZ) was 6,447.
On July 22nd, Gelunhui reported that as of July 19th, 2024, the total number of shareholders of Meihao Medical (301363.SZ) was 6,447, including 1,879 institutional shareholders.
Meihao Medical (301363.SZ): The US government's related tariff policies have not had a negative impact on the company's business.
On July 16th, Guolonghui reported that Mei Hao Medical (301363.SZ) stated on the investor interaction platform that the US government's relevant additional tariff policies have not had a negative impact on the company's business so far. Firstly, the company's main customers mainly operate factories in Singapore, Australia and other places, and the end products are exported from Singapore and Australia to the United States and other places for sales. Secondly, since the company built its first overseas production base in Malaysia in 2014, it has been orderly expanding production according to customer demand. Phase I and phase II workshops have been put into operation normally, and the end-to-end delivery capability of overseas production bases has been continuously strengthened. The construction of the third phase in Malaysia is currently being accelerated.
As of July 10th, there were 6,841 shareholders in Meihao Medical (301363.SZ) company.
On July 11th, Gelunhui reported that as of July 10, 2024, the total number of shareholders of Meihao Medical (301363.SZ) was 6,841, of which 2,194 were institutional shareholders.
Mei Hao Medical (301363.SZ): Plans to invest up to 80 million USD to build a phase three production base in Malaysia.
On July 10th, Gelonghui reported that Meheco Medical Science & Technology Co Ltd (301363.SZ) announced its global strategy to continuously strengthen and improve global industry layout, further enhance its competitiveness and service capabilities in overseas markets. The company plans to invest and build a third-phase production base in Malaysia through its wholly-owned subsidiary, Miman (Malaysia) Sdn Bhd, with a total planned investment of no more than 80 million US dollars, including but not limited to construction of production plant and purchase of fixed assets.
Mehow Innovative Ltd.'s (SZSE:301363) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?No Data
